Startup profile · funding coverage
Galvanize Therapeutics funding, valuation and investors
US medical-device company commercializing pulsed electric field instruments for soft-tissue ablation, while investigating chronic-lung and oncology applications.
Verified company research · funding, investors and latest developments
Keep track of Galvanize Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series D
$130M · November 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$330M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Redwood City, California, United States
Investors in latest funding
Lead: HealthQuest Capital
Other: Olympus Innovation Ventures , Braidwell LP , Sofinnova Partners , Norwest
Overview
Galvanize Therapeutics develops medical devices that use high-voltage, short-duration pulsed electric fields (PEF) to ablate soft tissue, rather than relying primarily on heat. Its FDA-cleared Aliya and Aliya EX surgical platforms are used by specialist physicians; it is also developing RheOx for chronic bronchitis. The September 2022 merger brought Gala Therapeutics, Galaxy Medical and Galvanize together.
On November 16, 2026 the company announced a closed, HealthQuest-led $130M Series D. Separate primary releases establish $100M Series B in 2022 and $100M Series C in 2025. Across these three identified rounds the disclosed sum is $330M, not necessarily lifetime financing. Product pricing, company revenue and the 2026 valuation have not been disclosed.
FDA 510(k) clearance for surgical ablation of soft tissue is not a disease-specific cancer treatment approval.
Why Galvanize Therapeutics is interesting
Galvanize announced a CLOSED $130M Series D on November 16, 2026, led by HealthQuest Capital. Unlike a purely preclinical biotech, its Aliya system is marketed under FDA soft-tissue-ablation 510(k) clearances. The disease-specific benefit and immune-effect hypotheses should not be confused with that clearance. The issuer reports over 4,000 procedures and over 300 PROPEL-registry enrollments, not 4,000 controlled-trial successes.
Product & use cases
For a surgical/interventional specialist: assess whether soft-tissue ablation is appropriate; obtain informed consent and select an anatomical target using clinical imaging and the indicated procedure; choose the Aliya EX pulse generator and compatible Aliya needle/electrode or INUMI Flex delivery tool; place the applicator during an endoscopic or percutaneous procedure following the approved IFU; deliver controlled electrical pulses locally and conduct follow-up monitoring. This is a documentation-derived illustrative clinical workflow, NOT hands-on testing or patient guidance. Galvanize does not disclose hospitals' equipment, disposables or reimbursement prices. FDA clearance covers surgical ablation of soft tissue only, and its own labeling disclaims established disease-specific treatment or immune-response benefit.
- Hospital use of FDA 510(k)-cleared Aliya/EX system for surgical ablation of soft tissue by trained physicians.
- PROPEL post-market registry and research tracking clinical use; registry enrollment is observational evidence, not randomized proof of cancer outcomes.
- Research/clinical development of RheOx PEF technology for chronic-bronchitis symptoms; applicable jurisdictions and status require separate device-specific review.
Key facts
- Closed $130M Series D announced 2026-11-16, led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell as new investors.
- Earlier original-company releases disclose $100M Series B (September 2022) and $100M Series C (September 2025). Three documented rounds total $330M; undisclosed earlier funding is excluded.
- Issuer reports over 4,000 Aliya procedures and more than 300 enrolled in PROPEL registry; counts are not efficacy endpoints or audited sales.
- FDA 510(k) K253826 cleared Aliya EX May 7, 2026 for surgical ablation of soft tissue, not for treatment/cure of a specified disease.
- Immune activation and disease-specific oncology benefit remain investigational; patient-benefit effectiveness has not been established.
Funding history (newest first)
Series D
2026-11-16 $130M- HealthQuest Capital (lead)
- Olympus Innovation Ventures (participant)
- Braidwell LP (participant)
- Sofinnova Partners (participant)
- Norwest (participant)
Source: Read source · prnewswire.com
Series C
2025-09-03 $100M- Sofinnova Partners (lead)
- Norwest (participant)
- Elevage Medical Technologies (participant)
- Ally Bridge Group (participant)
Source: Read source · prnewswire.com
Series B
2022-09-15 $100M- Fidelity Management & Research Company (lead)
- ATP (Apple Tree Partners) (participant)
- Intuitive Surgical (participant)
- Gilmartin Capital (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: The non-thermal PEF mechanism can preserve some surrounding structural tissue and differs operationally from radiofrequency/microwave/cryogenic thermal ablation, according to Galvanize's cited materials. The company's claims about predictability, immune stimulation or clinical superiority require comparative evidence; do not imply established patient-benefit improvement.
-
AngioDynamics NanoKnife direct
Another irreversible-electroporation soft-tissue ablation technology; indications, electrodes and evidence differ.
-
Radiofrequency ablation systems alternative
Established heat-based ablation modality; thermal injury and heat-sink considerations differ by anatomy.
-
Microwave ablation devices alternative
Heat-based ablation alternative with different procedural and anatomical tradeoffs.
-
Cryoablation systems alternative
Cold-based surgical ablation alternative; clinical selection is indication-specific.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Galvanize Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.